Skip to main content

Advertisement

SpringerLink
Log in

Gene expression in breast cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

We now recognize that all breast cancers are not the same. Different characteristics in gene expression profiles result in differential clinical behavior. With the use of gene microarrays, different subtypes of breast cancer have been characterized. The basal subtype is characterized by high expression of keratins 5 and 17, laminin, and fatty acid-binding protein 7. The ERBB2+ subtype is characterized by high expression of genes in the ERBB2 amplicon. The luminal A subtype is characterized by the highest expression of the ER α gene. The luminal B and C subtypes have a lower expression of the ER cluster. The importance of these different subtypes lies in the fact that they differ in clinical outcome, with the basal and ERBB2+ subtypes having the worse prognosis and the luminal A group having the best prognosis. Different strategies for evaluating tumors in a clinical setting have been developed. Two such strategies are the 21-gene assay (Oncotype DX; Genomic Health, Redwood City, CA), which is currently in commercial use in the United States, and the 70-gene assay, which has been developed by a group in the Netherlands. These assays have been shown to predict clinical outcome and response to therapy. However, to date these gene assays have not been studied in a prospective manner. Over the next year, prospective clinical trials will be initiated using these predictive tools in the treatment of breast cancer. In the near future, clinical decisions will most likely be dictated by the genetic characteristics of the tumor, with the clinical characteristics becoming less important. Tailoring our treatment based on individual tumor characteristics will help us develop better therapeutic strategies and save many patients from receiving unnecessary toxic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687–1717.

    Article  CAS  Google Scholar 

  2. Esteban JM, Baker JB, Cronin M, et al.: Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue. Proc Am Soc Clin Oncol 2003, 22:850.

    Google Scholar 

  3. Fisher B, Costantino J, Redmond C, et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989, 320:479–484.

    Article  PubMed  CAS  Google Scholar 

  4. Perou CM, Sorlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 2000, 406:747–752. This is the first report on tissue microarrays in breast cancer and the occurrence of different subtypes.

    Article  PubMed  CAS  Google Scholar 

  5. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869–10874. In this article, the authors further subclassify breast cancers into different subtypes according to tissue microarray data.

    Article  PubMed  CAS  Google Scholar 

  6. Paik S, Shak S, Tang G, et al.: Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients-NSABP studies B-20 and B-14. Breast Cancer Res Treat 2003, 82:A16.

    Google Scholar 

  7. Cronin M, Pho M, Dutta D, et al.: Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004, 164:35–42.

    PubMed  CAS  Google Scholar 

  8. van de Vijver MJ, He YD, van ’t Veer LJ, et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999–2009.

    Article  PubMed  Google Scholar 

  9. Rouzier R, Anderson K, Hess KR, et al.: Basal and luminal types of breast cancer defined by gene expression patterns respond differently to neoadjuvant chemotherapy [abstract 201]. Breast Cancer Res Treat 2004, 88(Suppl 1):S24.

    Google Scholar 

  10. Carey LA, Dees EC, Sawyer LR, et al.: The triple negative paradox: primary tumor chemosensitivity of the basal-like breast cancer phenotype [abstract 1023]. Breast Cancer Res Treat 2004, 88(Suppl 1):S48.

    Google Scholar 

  11. Carey LA, Kim NW, Goodman S, et al.: Telomerase activity and prognosis in primary breast cancers. J Clin Oncol 1999, 17:3075–3081.

    PubMed  CAS  Google Scholar 

  12. Simon R: Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer 2003, 89:1599–1604.

    Article  PubMed  CAS  Google Scholar 

  13. Cobleigh MA, Bitterman P, Baker JB, et al.: Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: high throughout RT-PCR assay of paraffin-embedded tumor tissues. Proc Am Soc Clin Oncol 2003, 22:850.

    Google Scholar 

  14. PaikS, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817–2826. Using molecular profiling in breast cancer, investigators were able to correlate prognosis with a recurrence score derived from the differential gene expression.

    Article  PubMed  CAS  Google Scholar 

  15. van’t Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530–536. Tissue microarrays are able to predict clinical outcome in breast cancer.

    Article  Google Scholar 

  16. Wang Y, Klijn JG, Zhang Y, et al.: Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. Lancet 2005, 365:671–679.

    PubMed  CAS  Google Scholar 

  17. Foekens JA, Atkins D, Sweep CGJ, et al.: Multi-center validation of the 76-gene prognostic signature in lymph node negative primary breast cancer. Breast Cancer Res Treat 2005, 94(Suppl 1):28.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Feinberg School of Medicine of Northwestern University and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Department of Medicine, Division of Hematology/Oncology, 676 North St. Clair Street, Suite 850, 60611, Chicago, IL, USA

    William J. Gradishar MD, FACP

Authors
  1. Virginia G. Kaklamani MD, DSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William J. Gradishar MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaklamani, V.G., Gradishar, W.J. Gene expression in breast cancer. Curr. Treat. Options in Oncol. 7, 123–128 (2006). https://doi.org/10.1007/s11864-006-0047-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-006-0047-0

Keywords

Search

Navigation